...
首页> 外文期刊>Leukemia and lymphoma >Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma
【24h】

Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma

机译:常规剂量化疗前小剂量前期治疗溃疡性胃弥漫性大B细胞淋巴瘤的安全性和有效性

获取原文
获取原文并翻译 | 示例
           

摘要

Potentially fatal chemotherapy (CT)-related gastrorrhagia and gastric perforation in patients with gastric lymphoma present difficult problems to doctors. We retrospectively analyzed 54 patients with ulcerative gastric diffuse large B-cell lymphoma (G-DLBCL) to compare the safety and efficacy of low-dose pre-phase CT before 4-6 cycles of conventional-dose CT (n = 28) with 4-6 cycles of conventional-dose CT (n = 26) between October 2005 and August 2014. Patients who received low-dose pre-phase before conventional-dose CT showed a lower gastrorrhagia or gastric perforation rate (0% vs. 15.4%, p = 0.047) and higher complete response (CR) rate (78.6% vs. 46.2%, p = 0.023) and 5-year progression-free survival (PFS) rate (63% vs. 31%, p = 0.021) than patients who received conventional-dose CT alone. Our study suggests that low-dose pre-phase therapy before conventional-dose CT provides a safe and effective method for ulcerative G-DLBCL.
机译:胃淋巴瘤患者潜在的致命性化学疗法(CT)相关性腹泻和胃穿孔给医生带来了难题。我们回顾性分析了54例溃疡性胃弥漫性大B细胞淋巴瘤(G-DLBCL)患者,以比较在常规剂量CT的4-6周期(n = 28)和4周期的低剂量前期CT的安全性和有效性在2005年10月至2014年8月之间进行了-6个周期的常规剂量CT检查(n = 26)。在常规剂量CT之前接受小剂量预治疗的患者出现较低的胃痛或胃穿孔率(0%对15.4%, p = 0.047)和比患者更高的完全缓解(CR)率(78.6%vs. 46.2%,p = 0.023)和5年无进展生存(PFS)率(63%vs. 31%,p = 0.021)他们仅接受常规剂量的CT检查。我们的研究表明,常规剂量CT之前的低剂量前期治疗为溃疡性G-DLBCL提供了一种安全有效的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号